Bourgeois B F
Naunyn Schmiedebergs Arch Pharmacol. 1986 Aug;333(4):406-11. doi: 10.1007/BF00500017.
In view of the trend towards single drug therapy of epilepsy, the experimental background for thr combination of phenobarbital (PB) and phenytoin (PHT) was reassessed. Since potentiation of the anticonvulsant activity is in itself neither sufficient nor necessary to demonstrate the superiority of a drug combination, protection against maximal electroshock seizures as well as neurotoxicity were determined in mice. This allowed one to separate the neurotoxic from the anticonvulsant interaction and to base the analysis on changes in the therapeutic index (TI). Pharmacokinetic interactions were excluded from the analysis by expressing all results in terms of brain concentrations. The anticonvulsant interaction between PB and PHT was found to be additive, whereas the neurotoxic interaction was antagonistic. These results provide experimental documentation of one of the theories behind antiepileptic drug combinations. However, because PB had a markedly lower TI than PHT in this model, the TI of the drug combination was lower than the TI of PHT. Thus, the antagonism with regard to neurotoxicity was not sufficient to raise the TI of the combination above the TI of PHT.
鉴于癫痫单药治疗的趋势,重新评估了苯巴比妥(PB)和苯妥英(PHT)联合使用的实验背景。由于抗惊厥活性的增强本身既不足以也不必要证明药物组合的优越性,因此在小鼠中测定了对最大电休克惊厥的保护作用以及神经毒性。这使得人们能够将神经毒性与抗惊厥相互作用区分开来,并基于治疗指数(TI)的变化进行分析。通过以脑浓度表示所有结果,将药代动力学相互作用排除在分析之外。发现PB和PHT之间的抗惊厥相互作用是相加的,而神经毒性相互作用是拮抗的。这些结果为抗癫痫药物联合使用背后的一种理论提供了实验依据。然而,由于在该模型中PB的TI明显低于PHT,药物组合的TI低于PHT的TI。因此,在神经毒性方面的拮抗作用不足以使组合的TI高于PHT的TI。